OXLUMO (lumasiran)
E1292059
UNEXPLORED
OXLUMO (lumasiran) is an RNA interference–based therapeutic used to reduce elevated oxalate levels in patients with primary hyperoxaluria type 1.
All labels observed (1)
| Label | Occurrences |
|---|---|
| OXLUMO (lumasiran) canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T17871417 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: OXLUMO (lumasiran) Context triple: [Alnylam Pharmaceuticals, Inc., develops, OXLUMO (lumasiran)]
-
A.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
B.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
C.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
-
D.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
E.
Iclusig
Iclusig is a cancer medication containing ponatinib, primarily used to treat certain types of leukemia such as chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: OXLUMO (lumasiran) Target entity description: OXLUMO (lumasiran) is an RNA interference–based therapeutic used to reduce elevated oxalate levels in patients with primary hyperoxaluria type 1.
-
A.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
B.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
C.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
-
D.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
E.
Iclusig
Iclusig is a cancer medication containing ponatinib, primarily used to treat certain types of leukemia such as chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
- F. None of above. chosen
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.